Dyne Therapeutics, Inc. (NASDAQ: DYN) shares move up the price scale Monday. The Waltham, Mass.-based company, a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DYNE-251 for the treatment of Duchenne muscular dystrophy (DMD) mutations amenable to exon 51 skipping. DYNE-251 is being evaluated in the Phase 1/2 DELIVER global clinical trial.
“Every day is critical for patients and their families, and we are pleased that the FDA granted Fast Track designation as this provides an opportunity to expedite the development of DYNE-251,” said Wildon Farwell, M.D., MPH, chief medical officer of Dyne.
The FDA grants Fast Track designation to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need, with the ultimate goal of getting important new drugs to patients earlier.
A drug that receives Fast Track designation may be eligible for more frequent meetings and communications with the FDA and rolling review of any application for marketing approval, which may lead to earlier drug approval and access by patients. A drug receiving Fast Track designation also may be eligible for Accelerated Approval and Priority Review if relevant criteria are met.
DYN shares gathered 15 cents, or 1.3%, in the first hour Monday to $11.73.
